Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 6 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors at 3 institutions in 3 countries.
Elena M LoiDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Ljubljana, 1000 Ljubljana, Slovenia.
Tihomir TomašičDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Ljubljana, 1000 Ljubljana, Slovenia.ORCID 0000-0001-5534-209X
Cyril BalsollierDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Ljubljana, 1000 Ljubljana, Slovenia.
Kevin van EekelenDepartment of Chemical Biology & Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CG Utrecht, The Netherlands.
Matjaž WeissDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Ljubljana, 1000 Ljubljana, Slovenia.ORCID 0000-0002-7900-3145
Martina GobecDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Ljubljana, 1000 Ljubljana, Slovenia.
Matthew G AlteenDepartment of Chemistry, Simon Fraser University, Burnaby, BC V5A 1S6, Canada.
David J VocadloDepartment of Chemistry, Simon Fraser University, Burnaby, BC V5A 1S6, Canada.
Roland J PietersDepartment of Chemical Biology & Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CG Utrecht, The Netherlands.ORCID 0000-0003-4723-3584
Marko AnderluhDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Ljubljana, 1000 Ljubljana, Slovenia.ORCID 0000-0003-1768-8246
University of Ljubljana · SISimon Fraser University · CAUtrecht University · NL
Funding
CIHR PJT-148732European Cooperation in Science and Technology CA18103European Cooperation in Science and Technology CA18132European Union's Horizon2020, Marie Skłodowska-Curie Actions ITN-EJD 765581Slovenian Research Agency P1-0208
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Discovery of a New Drug-like Series of OGT Inhibitors by Virtual Screening. · full record | OpenQuestion